-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read and reference ILD is an important cause of SSc morbidity and mortality
.
The European Union Against Rheumatism (EULAR) conference in 2021 will be held online, and rheumatology immunologists and doctors around the world will enjoy this academic feast
.
The "Medical Channel of Rheumatology and Kidney Disease" combined with authoritative experts from Peking University People's Hospital to report on the meeting in a timely manner, and to grasp the latest and hottest international frontier developments in the field of rheumatology and immunology for the first time
.
At the conference, Professor Toby Maher from the University of Southern California brought us a report entitled "Systemic sclerosis and lung involvement: diagnostic work-up and new treatment modalities"
.
Systemic sclerosis (SSc) is an autoimmune disease involving multiple systems
.
In addition to skin involvement, lung involvement is a common manifestation, manifested as interstitial pulmonary disease (ILD), which aggravates with the expansion of the affected area
.
When we compared the lung pathology of normal lung and SSc-ILD, we found that the alveolar interval of SSc-ILD was significantly thickened, which caused symptoms such as dyspnea
.
The patient’s dyspnea symptoms aggravated as the extent of the thickening of the lung septum increased
.
ILD is the main cause of death of SSc.
In 2010, EULAR conducted a study on the cause of death of patients in the SSc follow-up database.
Among the 234 SSc patients who died in the study, 128 died of the SSc disease itself, of which 78 were deaths.
Lung involvement (45 cases died of ILD, 33 cases died of pulmonary hypertension)
.
Figure 1: ILD is the main cause of death for SSc.
The Norwegian national SSc cohort study shows that ILD is strongly correlated with the decrease in the 10-year survival rate of SSc
.
Studies have shown that compared with SSC patients without ILD, the 10-year survival rate of SSC patients with any degree of ILD is reduced by 60%
.
Figure 2: The 10-year survival rate of SS patients with ILD has significantly decreased.
Steen et al
.
studied the causes of death in SSc patients who died between 1997 and 2001 .
In 1972-1976, 1977-1981 and 1982-1986, renal crisis was the main cause of death of SSc, but during 1987-1991, pulmonary hypertension was the main cause of death of SSs
.
From 1992-1996 to 1997-2001, ILD gradually replaced pulmonary hypertension and became the main cause of death in SSc
.
Figure 3: In recent years, ILD has gradually replaced renal crisis, and pulmonary hypertension has become the main cause of death in SSc.
Consensus on the management of SSc-ILD In 2021, the Delphi expert survey method developed a draft consensus on the management of SSc-ILD
.
This guide adopts the Delphi expert survey method, systematically reviewed 280 documents on SSc-lLD (published from January 1992 to April 2018), and used it to establish 95 evidence-based draft statements to review consensus statements
.
The consensus development draft was tested in six areas: risk factors, disease screening, disease diagnosis and severity assessment, first-line treatment drug selection, disease progression assessment, and second-line treatment drug selection
.
What does the consensus say? 1.
Which risk factors increase the risk of ILD? Respiratory symptoms, smoking history, genetic factors (Native American, African inheritance), maleness, diffuse skin sclerosis, and Scl-70 antibody positive are positively correlated with the increased risk of ILD
.
Patients with positive anticentromere antibodies are less likely to develop ILD
.
Figure 4: Six high-risk factors for developing ILD 2.
When and how should patients with SSc undergo ILD screening? All patients should be carefully auscultated during physical examination, and high-resolution CT examination and pulmonary function examination should be perfected.
Forced vital capacity (FVC) and carbon monoxide diffusion capacity (DLco) can provide baseline disease data
.
The frequency of rechecking HRCT and lung function should be determined by the clinician based on the situation
.
3.
How should the severity be diagnosed and evaluated? The main tools for evaluating the presence or absence of ILD in SSc patients are HRCT and pulmonary function tests, and clinical assessment of respiratory symptoms is also an auxiliary diagnosis method
.
A variety of methods should be used to assess the severity, including: HRCT manifestations, respiratory symptoms, exercise-induced oxygen saturation reduction, and quality of life
.
4.
Extensive pulmonary involvement and FVC reduction of ≥10% are predictors of poor prognosis.
Compared with SSc patients with extensive pulmonary involvement and local pulmonary involvement, the 10-year survival rate can be significantly reduced (75% VS 30%), within 12 months There is also a significant difference in the 10-year survival rate of patients with FVC lower than 10% and FVC lower than 10%
.
Figure 5: How to treat the SSc-lLD predictor of death? 1 Cyclophosphamide Cyclophosphamide is the main therapeutic drug for SSc-ILD
.
In 2006, the New England Journal of Medicine published an SLS I study of cyclophosphamide and placebo in the treatment of SSc-ILD
.
The subjects of the study were patients with active alveolitis, FVC 45%-85% and> Grade 2 dyspnea as suggested by SSc-ILD, BAL or CT
.
The intervention measures are: oral cyclophosphamide 2mg/kg/d VS placebo treatment for 12 months
.
The primary endpoint of the study: FVC changes at baseline and week 52
.
Secondary endpoints: 1.
Pulmonary function measurement; 2.
Dyspnea score; 3.
Quality of life score
.
Figure 6: The classic study of cyclophosphamide in the treatment of SSc-ILD showed that at 12 months of treatment, the proportion of patients in the cyclophosphamide group (49.
3%) of baseline FVC increase was greater than that of the placebo group (26.
4%)
.
However, when the cyclophosphamide treatment was discontinued after 12 months and the placebo treatment was continued to the 24th month, there was no difference in the improvement of FVC between the experimental group and the placebo group
.
This finding suggests that the efficacy of cyclophosphamide gradually declines in the case of non-sequential treatment after stopping the drug
.
Figure 7: Patients in the cyclophosphamide group received 1 year of cyclophosphamide followed by sequential placebo treatment for 1 year
.
At 24 months of treatment, there was no difference between FVC improvement and placebo group.
The two groups of patients in the SLS I study were further followed up to the 144th month
.
The comparison found that the survival curve of patients in the cyclophosphamide treatment group was not significantly different from that of the control group
.
Figure 8: The survival curve of SSC-lLD in the cyclophosphamide treatment group was not significantly different from that in the control group.
2 Mycophenolate mofetil studies have shown that mycophenolate mofetil treatment averages 250-200 weeks before and after treatment of ILD (RA, SSc/PM/DM).
The patient's FVC% has improved
.
Figure 9: Mycophenolate mofetil treatment of ILD can improve FVC% In 2016, Lancet published a randomized controlled, double-blind, parallel study (SLS II) comparing mycophenolate mofetil and oral cyclophosphamide in the treatment of SSc-ILD
.
Studies have shown that mycophenolate mofetil and cyclophosphamide have similar therapeutic effects (at 12 and 24 months), but mycophenolate mofetil is better tolerated
.
Figure 10: Mycophenolate mofetil is better tolerated in the treatment of ILD.
3 The rituximab RECITAL study is a multi-center, prospective, randomized, double-blind, double-dummy, controlled trial in the UK.
This is the first RCT trial To study the efficacy of rituximab as the first-line treatment of CTD-related ILD
.
The results of the mid-term study showed that after 6 to 12 months of treatment with rituximab, an increase in FVC can be observed
.
Although the final research results have not come out, I still look forward to the research results will be published at a conference this year
.
Figure 11: Rituximab treatment of ILD can increase FVC% 4 Tocilizumab A subcutaneous injection of tocilizumab in the treatment of SSc safety and effectiveness Phase 2, randomized controlled study showed: compared with placebo group , Tocilizumab has nothing to do with the improvement of SSc skin thickening, but fewer patients predicted a decrease in FVC% at 48 weeks of treatment with tocilizumab (p=0.
0373)
.
Figure 12: Tocilizumab can prevent FVC% reduction in the early stage.
After the Phase 2 trial of Tocilizumab showed preliminary evidence for the effectiveness of SSc, the researchers also evaluated tocilizumab for the treatment of SSc-ILD in the Phase 3 trial.
The safety and effectiveness
.
The results of the phase 3 study showed that compared with the placebo group, tocilizumab can protect the lung function of early SSc-ILD and reduce the decline of FVC
.
The safety of the drug is consistent with the previously known tocilizumab
.
5 Bone marrow transplantation A non-randomized study of hematopoietic stem cell transplantation (HSCT) for the treatment of SSc showed that lung function and skin elasticity were improved, but treatment-related mortality was higher
.
An open-label randomized phase 2 trial comparing autologous non-myeloablative hematopoietic stem cell transplantation with monthly pulsed cyclophosphamide in the treatment of systemic sclerosis (ASSIST) showed that all 10 patients who received HSCT had a 12-month follow-up There was improvement, but none of the 9 patients treated with cyclophosphamide improved
.
Compared with patients who did not receive HSCT treatment, 8 patients in the 9 control group developed disease progression
.
Compared with baseline, 11 patients were followed up for 2 years after HSCT, and their mRSS (p<0.
0001) and forced vital capacity (p<0.
03) continued to improve
.
In general, non-myeloablative autologous HSCT can improve the skin and lung function of SSc patients for up to 2 years, which is better than the current standard treatment effect, but requires longer follow-up
.
Figure 13: Bone marrow transplantation is better than standard treatment for SSc-ILD.
6 Lung transplantation.
Lung transplantation is a feasible and potentially life-saving method for the treatment of SSc patients with end-stage ILD
.
However, multiple complications (including gastroesophageal reflux, dyskinesia, renal impairment, skin rupture caused by ulcers, and arrhythmia) increase the risk of surgery-related death
.
In recent years, studies have shown that the 5-year survival rate of SSc-ILD patients undergoing lung transplantation is not significantly different from that of the placebo group
.
Figure 14 Lung transplantation does not improve the 5-year survival rate of patients.
However, the efficacy and safety study of nintedanib in Asian patients with SSc-ILD in November 2020 provides a better option
.
In the SENSCIS trial of SSc-ILD patients, compared with the placebo group, the nintedanib treatment group improved the FVC decline rate by 44% after 52 weeks, and the adverse events of most patients were controllable
.
At present, Europe and the United States have approved the use of nintedanib for the treatment of SSc-ILD
.
Figure 15: Nintedanib can effectively improve the FVC% of patients with SSc-ILD.
Therefore, affected by this, the speaker currently supports the treatment of SSc-ILD as follows: 1.
Mild and/or slowly progressive SSc-ILD: Nil Danib + mycophenolate mofetil; 2.
Extensive/rapidly progressive SSc-ILD: Tocilizumab is used for signs of systemic inflammation and SSc-ILD progresses rapidly; in other cases, in nintedanib + mycophenolic acid After the ester, rituximab or cyclophosphamide is added according to the situation
.
Note: (The above treatment is not officially approved for the treatment of SSc-ILD) Summary: 1.
ILD is an important cause of SSc morbidity and mortality
.
2.
HRCT and lung function should be used to evaluate the prognosis of SSc-ILD when diagnosing SSc
.
3.
The treatment options include cyclophosphamide, MMF, nintedanib, and tocilizumab
.
Rituximab may also be effective, and nintedanib has been approved for the treatment of SSc-ILD in Europe and the United States
.
Experts comment that SSc is a relatively common systemic connective tissue disease (CTD)
.
In recent years, ILD has gradually replaced renal crisis and pulmonary hypertension as the main cause of death in SSc patients
.
How to diagnose and treat SSc-ILD has always been a hot and difficult point in the field of SSc treatment
.
From another perspective, SSc-ILD is one of the few diseases in CTD-ILD with high-level evidence-based medicine.
Its classic SLS I, SLS II, RECITAL, faSScinate, ASSIST, SENSCIS and other studies are also Other clinical decisions of CTD-ILD provide important references
.
In recent years, scholars from various countries have made in-depth studies on the clinical features, diagnostic methods, and drug treatment effects of SSc-ILD and have gradually drawn a clearer outline of the disease
.
We are pleased to see that on the basis of these studies, the management consensus of SSc-ILD came into being
.
Consensus elaborates on the identification of high-risk groups, screening and diagnosis of ILD, disease evaluation and prognosis analysis, and treatment options, and provides important theoretical guidance for the individualized evaluation and treatment options of SSc-ILD
.
Expert profile Professor Yang Yue, deputy chief physician of the Department of Rheumatology and Immunology, Peking University People’s Hospital, associate professor, Harvard Medical School, postdoctoral fellow at Massachusetts General Hospital, and international researcher of the American Academy of Rheumatology participated in the drafting of the Asia Pacific Association of Rheumatology (APLAR) Rheumatoid Arthritis Treatment Guidelines, Compilation of "Kelly's Rheumatology" and "Harrison's Rheumatology", "Clinical Rheumatology Handbook" and other writings, Executive Deputy Editor-in-chief of APLAR official newspaper, Uptodate Chinese version contracted translation expert, Young editor of "Journal of Guangzhou Medical University" Committee, domestic and foreign journal review experts published more than 30 academic papers in both Chinese and English.
Hosted the National Natural Science Foundation of China and the Ministry of Education’s Doctoral New Teacher Fund.
He has spoken many times at APLAR, CROI, Keystone and other international academic conferences and won international scholarships.
, "Young Researcher" Award, "Best Abstract Award" for many times, mainly good at diagnosis and treatment of common and rare rheumatism such as rheumatoid arthritis, Sjogren's syndrome, connective tissue disease-related pulmonary interstitial lesions, etc.
.
The European Union Against Rheumatism (EULAR) conference in 2021 will be held online, and rheumatology immunologists and doctors around the world will enjoy this academic feast
.
The "Medical Channel of Rheumatology and Kidney Disease" combined with authoritative experts from Peking University People's Hospital to report on the meeting in a timely manner, and to grasp the latest and hottest international frontier developments in the field of rheumatology and immunology for the first time
.
At the conference, Professor Toby Maher from the University of Southern California brought us a report entitled "Systemic sclerosis and lung involvement: diagnostic work-up and new treatment modalities"
.
Systemic sclerosis (SSc) is an autoimmune disease involving multiple systems
.
In addition to skin involvement, lung involvement is a common manifestation, manifested as interstitial pulmonary disease (ILD), which aggravates with the expansion of the affected area
.
When we compared the lung pathology of normal lung and SSc-ILD, we found that the alveolar interval of SSc-ILD was significantly thickened, which caused symptoms such as dyspnea
.
The patient’s dyspnea symptoms aggravated as the extent of the thickening of the lung septum increased
.
ILD is the main cause of death of SSc.
In 2010, EULAR conducted a study on the cause of death of patients in the SSc follow-up database.
Among the 234 SSc patients who died in the study, 128 died of the SSc disease itself, of which 78 were deaths.
Lung involvement (45 cases died of ILD, 33 cases died of pulmonary hypertension)
.
Figure 1: ILD is the main cause of death for SSc.
The Norwegian national SSc cohort study shows that ILD is strongly correlated with the decrease in the 10-year survival rate of SSc
.
Studies have shown that compared with SSC patients without ILD, the 10-year survival rate of SSC patients with any degree of ILD is reduced by 60%
.
Figure 2: The 10-year survival rate of SS patients with ILD has significantly decreased.
Steen et al
.
studied the causes of death in SSc patients who died between 1997 and 2001 .
In 1972-1976, 1977-1981 and 1982-1986, renal crisis was the main cause of death of SSc, but during 1987-1991, pulmonary hypertension was the main cause of death of SSs
.
From 1992-1996 to 1997-2001, ILD gradually replaced pulmonary hypertension and became the main cause of death in SSc
.
Figure 3: In recent years, ILD has gradually replaced renal crisis, and pulmonary hypertension has become the main cause of death in SSc.
Consensus on the management of SSc-ILD In 2021, the Delphi expert survey method developed a draft consensus on the management of SSc-ILD
.
This guide adopts the Delphi expert survey method, systematically reviewed 280 documents on SSc-lLD (published from January 1992 to April 2018), and used it to establish 95 evidence-based draft statements to review consensus statements
.
The consensus development draft was tested in six areas: risk factors, disease screening, disease diagnosis and severity assessment, first-line treatment drug selection, disease progression assessment, and second-line treatment drug selection
.
What does the consensus say? 1.
Which risk factors increase the risk of ILD? Respiratory symptoms, smoking history, genetic factors (Native American, African inheritance), maleness, diffuse skin sclerosis, and Scl-70 antibody positive are positively correlated with the increased risk of ILD
.
Patients with positive anticentromere antibodies are less likely to develop ILD
.
Figure 4: Six high-risk factors for developing ILD 2.
When and how should patients with SSc undergo ILD screening? All patients should be carefully auscultated during physical examination, and high-resolution CT examination and pulmonary function examination should be perfected.
Forced vital capacity (FVC) and carbon monoxide diffusion capacity (DLco) can provide baseline disease data
.
The frequency of rechecking HRCT and lung function should be determined by the clinician based on the situation
.
3.
How should the severity be diagnosed and evaluated? The main tools for evaluating the presence or absence of ILD in SSc patients are HRCT and pulmonary function tests, and clinical assessment of respiratory symptoms is also an auxiliary diagnosis method
.
A variety of methods should be used to assess the severity, including: HRCT manifestations, respiratory symptoms, exercise-induced oxygen saturation reduction, and quality of life
.
4.
Extensive pulmonary involvement and FVC reduction of ≥10% are predictors of poor prognosis.
Compared with SSc patients with extensive pulmonary involvement and local pulmonary involvement, the 10-year survival rate can be significantly reduced (75% VS 30%), within 12 months There is also a significant difference in the 10-year survival rate of patients with FVC lower than 10% and FVC lower than 10%
.
Figure 5: How to treat the SSc-lLD predictor of death? 1 Cyclophosphamide Cyclophosphamide is the main therapeutic drug for SSc-ILD
.
In 2006, the New England Journal of Medicine published an SLS I study of cyclophosphamide and placebo in the treatment of SSc-ILD
.
The subjects of the study were patients with active alveolitis, FVC 45%-85% and> Grade 2 dyspnea as suggested by SSc-ILD, BAL or CT
.
The intervention measures are: oral cyclophosphamide 2mg/kg/d VS placebo treatment for 12 months
.
The primary endpoint of the study: FVC changes at baseline and week 52
.
Secondary endpoints: 1.
Pulmonary function measurement; 2.
Dyspnea score; 3.
Quality of life score
.
Figure 6: The classic study of cyclophosphamide in the treatment of SSc-ILD showed that at 12 months of treatment, the proportion of patients in the cyclophosphamide group (49.
3%) of baseline FVC increase was greater than that of the placebo group (26.
4%)
.
However, when the cyclophosphamide treatment was discontinued after 12 months and the placebo treatment was continued to the 24th month, there was no difference in the improvement of FVC between the experimental group and the placebo group
.
This finding suggests that the efficacy of cyclophosphamide gradually declines in the case of non-sequential treatment after stopping the drug
.
Figure 7: Patients in the cyclophosphamide group received 1 year of cyclophosphamide followed by sequential placebo treatment for 1 year
.
At 24 months of treatment, there was no difference between FVC improvement and placebo group.
The two groups of patients in the SLS I study were further followed up to the 144th month
.
The comparison found that the survival curve of patients in the cyclophosphamide treatment group was not significantly different from that of the control group
.
Figure 8: The survival curve of SSC-lLD in the cyclophosphamide treatment group was not significantly different from that in the control group.
2 Mycophenolate mofetil studies have shown that mycophenolate mofetil treatment averages 250-200 weeks before and after treatment of ILD (RA, SSc/PM/DM).
The patient's FVC% has improved
.
Figure 9: Mycophenolate mofetil treatment of ILD can improve FVC% In 2016, Lancet published a randomized controlled, double-blind, parallel study (SLS II) comparing mycophenolate mofetil and oral cyclophosphamide in the treatment of SSc-ILD
.
Studies have shown that mycophenolate mofetil and cyclophosphamide have similar therapeutic effects (at 12 and 24 months), but mycophenolate mofetil is better tolerated
.
Figure 10: Mycophenolate mofetil is better tolerated in the treatment of ILD.
3 The rituximab RECITAL study is a multi-center, prospective, randomized, double-blind, double-dummy, controlled trial in the UK.
This is the first RCT trial To study the efficacy of rituximab as the first-line treatment of CTD-related ILD
.
The results of the mid-term study showed that after 6 to 12 months of treatment with rituximab, an increase in FVC can be observed
.
Although the final research results have not come out, I still look forward to the research results will be published at a conference this year
.
Figure 11: Rituximab treatment of ILD can increase FVC% 4 Tocilizumab A subcutaneous injection of tocilizumab in the treatment of SSc safety and effectiveness Phase 2, randomized controlled study showed: compared with placebo group , Tocilizumab has nothing to do with the improvement of SSc skin thickening, but fewer patients predicted a decrease in FVC% at 48 weeks of treatment with tocilizumab (p=0.
0373)
.
Figure 12: Tocilizumab can prevent FVC% reduction in the early stage.
After the Phase 2 trial of Tocilizumab showed preliminary evidence for the effectiveness of SSc, the researchers also evaluated tocilizumab for the treatment of SSc-ILD in the Phase 3 trial.
The safety and effectiveness
.
The results of the phase 3 study showed that compared with the placebo group, tocilizumab can protect the lung function of early SSc-ILD and reduce the decline of FVC
.
The safety of the drug is consistent with the previously known tocilizumab
.
5 Bone marrow transplantation A non-randomized study of hematopoietic stem cell transplantation (HSCT) for the treatment of SSc showed that lung function and skin elasticity were improved, but treatment-related mortality was higher
.
An open-label randomized phase 2 trial comparing autologous non-myeloablative hematopoietic stem cell transplantation with monthly pulsed cyclophosphamide in the treatment of systemic sclerosis (ASSIST) showed that all 10 patients who received HSCT had a 12-month follow-up There was improvement, but none of the 9 patients treated with cyclophosphamide improved
.
Compared with patients who did not receive HSCT treatment, 8 patients in the 9 control group developed disease progression
.
Compared with baseline, 11 patients were followed up for 2 years after HSCT, and their mRSS (p<0.
0001) and forced vital capacity (p<0.
03) continued to improve
.
In general, non-myeloablative autologous HSCT can improve the skin and lung function of SSc patients for up to 2 years, which is better than the current standard treatment effect, but requires longer follow-up
.
Figure 13: Bone marrow transplantation is better than standard treatment for SSc-ILD.
6 Lung transplantation.
Lung transplantation is a feasible and potentially life-saving method for the treatment of SSc patients with end-stage ILD
.
However, multiple complications (including gastroesophageal reflux, dyskinesia, renal impairment, skin rupture caused by ulcers, and arrhythmia) increase the risk of surgery-related death
.
In recent years, studies have shown that the 5-year survival rate of SSc-ILD patients undergoing lung transplantation is not significantly different from that of the placebo group
.
Figure 14 Lung transplantation does not improve the 5-year survival rate of patients.
However, the efficacy and safety study of nintedanib in Asian patients with SSc-ILD in November 2020 provides a better option
.
In the SENSCIS trial of SSc-ILD patients, compared with the placebo group, the nintedanib treatment group improved the FVC decline rate by 44% after 52 weeks, and the adverse events of most patients were controllable
.
At present, Europe and the United States have approved the use of nintedanib for the treatment of SSc-ILD
.
Figure 15: Nintedanib can effectively improve the FVC% of patients with SSc-ILD.
Therefore, affected by this, the speaker currently supports the treatment of SSc-ILD as follows: 1.
Mild and/or slowly progressive SSc-ILD: Nil Danib + mycophenolate mofetil; 2.
Extensive/rapidly progressive SSc-ILD: Tocilizumab is used for signs of systemic inflammation and SSc-ILD progresses rapidly; in other cases, in nintedanib + mycophenolic acid After the ester, rituximab or cyclophosphamide is added according to the situation
.
Note: (The above treatment is not officially approved for the treatment of SSc-ILD) Summary: 1.
ILD is an important cause of SSc morbidity and mortality
.
2.
HRCT and lung function should be used to evaluate the prognosis of SSc-ILD when diagnosing SSc
.
3.
The treatment options include cyclophosphamide, MMF, nintedanib, and tocilizumab
.
Rituximab may also be effective, and nintedanib has been approved for the treatment of SSc-ILD in Europe and the United States
.
Experts comment that SSc is a relatively common systemic connective tissue disease (CTD)
.
In recent years, ILD has gradually replaced renal crisis and pulmonary hypertension as the main cause of death in SSc patients
.
How to diagnose and treat SSc-ILD has always been a hot and difficult point in the field of SSc treatment
.
From another perspective, SSc-ILD is one of the few diseases in CTD-ILD with high-level evidence-based medicine.
Its classic SLS I, SLS II, RECITAL, faSScinate, ASSIST, SENSCIS and other studies are also Other clinical decisions of CTD-ILD provide important references
.
In recent years, scholars from various countries have made in-depth studies on the clinical features, diagnostic methods, and drug treatment effects of SSc-ILD and have gradually drawn a clearer outline of the disease
.
We are pleased to see that on the basis of these studies, the management consensus of SSc-ILD came into being
.
Consensus elaborates on the identification of high-risk groups, screening and diagnosis of ILD, disease evaluation and prognosis analysis, and treatment options, and provides important theoretical guidance for the individualized evaluation and treatment options of SSc-ILD
.
Expert profile Professor Yang Yue, deputy chief physician of the Department of Rheumatology and Immunology, Peking University People’s Hospital, associate professor, Harvard Medical School, postdoctoral fellow at Massachusetts General Hospital, and international researcher of the American Academy of Rheumatology participated in the drafting of the Asia Pacific Association of Rheumatology (APLAR) Rheumatoid Arthritis Treatment Guidelines, Compilation of "Kelly's Rheumatology" and "Harrison's Rheumatology", "Clinical Rheumatology Handbook" and other writings, Executive Deputy Editor-in-chief of APLAR official newspaper, Uptodate Chinese version contracted translation expert, Young editor of "Journal of Guangzhou Medical University" Committee, domestic and foreign journal review experts published more than 30 academic papers in both Chinese and English.
Hosted the National Natural Science Foundation of China and the Ministry of Education’s Doctoral New Teacher Fund.
He has spoken many times at APLAR, CROI, Keystone and other international academic conferences and won international scholarships.
, "Young Researcher" Award, "Best Abstract Award" for many times, mainly good at diagnosis and treatment of common and rare rheumatism such as rheumatoid arthritis, Sjogren's syndrome, connective tissue disease-related pulmonary interstitial lesions, etc.
